FDA Grants Approval for Mirabegron ANDA219941 by Deva Holding AS
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219941 for Mirabegron submitted by Deva Holding AS.
Asset
Mirabegron
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of a generic version of Mirabegron by Deva Holding AS signifies increased competition in the overactive bladder market. This could impact pricing strategies and market share for existing branded products, necessitating close monitoring by portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake of the generic and any subsequent pricing strategies from competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.